Are weight loss pills as effective as injections? What the evidence shows

Step 1: understand what each type of medicine actually does

Both oral and injectable GLP-1 medicines work by mimicking gut hormones that regulate appetite and slow gastric emptying. Injections deliver the active ingredient directly into subcutaneous fat, where absorption is predictable and consistent. Tablets face a harder journey: the active compound must survive the acidic environment of the stomach, cross the gut wall, and reach the bloodstream in useful quantities. That is why the Wegovy tablet's maintenance dose is 25mg (far higher than the 2.4mg weekly injection) and why the administration instructions are precise.

Tirzepatide, available as Mounjaro in the UK, adds a second mechanism: it activates both GLP-1 and GIP receptors. That dual action appears to explain why its trial results sit above either semaglutide formulation. A question our prescribers hear most weeks is whether switching from tablets to injections (or the reverse) is simply a matter of preference. The honest answer is that the two are not interchangeable; they differ in both mechanism and real-world efficacy, and the right choice depends on more than convenience alone.

You can read more about how effective weight loss injections are in detail on a dedicated page, including the trial figures by dose and medicine.

Step 2: look at what the trial data actually says, dose by dose

Clinical trial results give us the clearest comparison available, though they are not a promise of what any individual will experience. In the STEP 1 trial, published in the New England Journal of Medicine, weekly 2.4mg semaglutide injections produced an average body-weight reduction of around 15% over 68 weeks. The SURMOUNT-1 trial, also in the NEJM, showed tirzepatide at its highest dose achieving average reductions of around 20–21% over 72 weeks, across thousands of adult participants.

The OASIS 4 trial (the phase 3 study underpinning the Wegovy tablet's approval) ran for 64 weeks and reported an average weight loss of approximately 13.6% compared with around 2.4% on placebo. Among participants who adhered fully to the regimen, results reached roughly 17%. That distinction matters: the injectable trials also assume weekly use, but the injection sits in the fridge and requires one action a week. The tablet requires a specific morning ritual, every single day, and any deviation can reduce absorption.

If you are weighing up the relative effectiveness of tablets versus injections for your own situation, those average figures are the starting point, but real-world adherence, individual metabolism, and diet and activity patterns all shape actual outcomes.

Step 3: consider the practical differences that affect real results

On paper, the injection has a small efficacy advantage on current evidence. In practice, the picture is more nuanced. Some people find a daily tablet easier to fit into a routine than a weekly injection, particularly those with needle anxiety. The Wegovy tablet needs no refrigeration, which simplifies travel. These are genuine quality-of-life factors, and they influence whether someone stays on treatment long enough to see meaningful results.

On the other hand, the tablet's strict administration window (first thing in the morning, empty stomach, plain water only, nothing else for at least 30 minutes) is a real-world constraint. Forget the order of events on a busy morning and absorption drops. Injections, once the technique is established, are simpler in that respect: one dose, once a week, stored in the fridge. You can explore how weight loss injections work and what the process looks like in practice.

Cost is another practical consideration. Context on what weight loss injections cost is worth reading alongside any comparison, because pricing varies by dose, provider, and what is included in the price. At nume, one transparent price covers the consultation, prescription, treatment, and free next-working-day tracked delivery, no hidden fees, no subscription.

Step 4: get a clinical view, not just a comparison table

Comparing trial averages is useful, but no published figure tells you how your body will respond. A prescriber looks at your BMI, your weight-related health conditions, whether you take other medicines (the tablet and some injections can affect absorption of oral contraceptives, for example), and your own preferences. That clinical picture determines which medicine is appropriate, and at what starting dose.

For most adults, eligibility for either formulation requires a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Individual results vary considerably, and a prescriber will set realistic expectations based on your starting point.

The NHS tirzepatide medicines page and the equivalent page for semaglutide cover the licensed indications and common side effects for each, a practical reference before any consultation. If you want to dig further into whether oral weight loss medications are as effective as injections, that question is covered in detail and is worth reading before any consultation. The right answer to the pills-versus-injections question, for you specifically, comes from that conversation rather than from a league table of percentages.